Published in Br J Haematol on August 01, 1997
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene (2001) 3.44
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19
Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood (1994) 2.16
Value of multiplex PCR using cerebrospinal fluid for the diagnosis of ventriculostomy-related meningitis in neurosurgery patients. Infection (2014) 2.09
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol (2004) 2.07
TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene (1999) 2.05
EVIDENCE FOR AN UNSTABLE CO(2) FIXATION PRODUCT IN ALGAL CELLS. Proc Natl Acad Sci U S A (1957) 1.97
Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol (2001) 1.89
Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. J Immunol (1996) 1.86
Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost (2008) 1.80
Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79
Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood (1989) 1.74
Pleiotropic changes controlled by the pre-T-cell receptor. Curr Opin Immunol (1999) 1.71
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am (2000) 1.69
Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood (1988) 1.69
Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J (2003) 1.64
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol (2004) 1.62
Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease. Scand J Gastroenterol (2004) 1.60
CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer (2002) 1.59
Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol (2005) 1.58
Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol (1995) 1.58
Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol (1996) 1.55
Interleukin-12 inhibits apoptosis in chronic lymphatic leukemia (CLL) B cells. Cancer Biother Radiopharm (2002) 1.55
Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer (2011) 1.53
Centriole overduplication through the concurrent formation of multiple daughter centrioles at single maternal templates. Oncogene (2007) 1.52
Identification and characterization of 20 immunocompetent patients with simultaneous varicella zoster and herpes simplex virus infection. J Eur Acad Dermatol Venereol (2008) 1.52
SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia (2013) 1.50
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50
HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia (2000) 1.49
Aetiology of tuberculids. Lancet (1993) 1.45
Essential role of the pre-T cell receptor in allelic exclusion of the T cell receptor beta locus. Immunity (1997) 1.44
Soluble tumour necrosis factor receptors as prognostic factors in cancer patients. Lancet (1994) 1.43
p53 protein in benign and malignant sweat gland tumors. Am J Dermatopathol (1994) 1.42
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer (2001) 1.42
Fosfomycin does not reduce cytostatic activity of cis-platinum against human osteosarcoma cell lines in vitro. Pediatr Hematol Oncol (1992) 1.41
Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes. Diabetologia (2003) 1.41
Neuropsychiatric symptoms during treatment with interleukin-2 and interferon-alpha. Lancet (1993) 1.40
Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. Br J Haematol (1995) 1.39
Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication. Oncogene (2006) 1.39
SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia (2011) 1.38
Inhibition of a pacemaker during nerve stimulation for regional anaesthesia. Anaesthesia (2007) 1.38
Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol (2013) 1.33
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
Outbreak due to a Klebsiella pneumoniae strain harbouring KPC-2 and VIM-1 in a German university hospital, July 2010 to January 2011. Euro Surveill (2011) 1.30
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia (2004) 1.28
Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res (1992) 1.27
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. Genes Immun (2006) 1.26
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol Cell Biol (2004) 1.25
Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol (1998) 1.25
Current practice of hemodynamic monitoring and vasopressor and inotropic therapy in post-operative cardiac surgery patients in Germany: results from a postal survey. Acta Anaesthesiol Scand (2006) 1.25
GARP: a key receptor controlling FOXP3 in human regulatory T cells. J Cell Mol Med (2009) 1.25
In vivo description of dendritic cells in human renal cell carcinoma. J Urol (1999) 1.23
EARLY UNSTABLE CO(2) FIXATION PRODUCTS IN PHOTOSYNTHESIS. Proc Natl Acad Sci U S A (1958) 1.23
The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J Exp Med (1997) 1.22
Consensus conference on European preparedness for haematological and other medical management of mass radiation accidents. Ann Hematol (2006) 1.21
Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia (2007) 1.21
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol (2010) 1.20
Fingerprints of anergic T cells. Curr Biol (2001) 1.19
Crucial function of the pre-T-cell receptor (TCR) in TCR beta selection, TCR beta allelic exclusion and alpha beta versus gamma delta lineage commitment. Immunol Rev (1998) 1.19
Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia (2003) 1.19
On the role of the pre-T cell receptor in alphabeta versus gammadelta T lineage commitment. Immunity (1998) 1.19
Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol (2000) 1.17
High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol (2010) 1.17
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol (1999) 1.16
Molecular subtyping of Borrelia burgdorferi in erythema migrans and acrodermatitis chronica atrophicans. J Invest Dermatol (1994) 1.16
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol (2004) 1.15
S3 guidelines for intensive care in cardiac surgery patients: hemodynamic monitoring and cardiocirculary system. Ger Med Sci (2010) 1.14
Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant (2010) 1.14
Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood (2000) 1.14
Defective in vitro growth of the hemopoietic progenitor cells in the acquired immunodeficiency syndrome. J Clin Invest (1987) 1.13
Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis. J Cutan Pathol (2001) 1.11
Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol (2002) 1.10
Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol (1996) 1.10
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol (2005) 1.10
Effects of brain-derived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development. J Neurochem (2005) 1.09
Quantitative determination of lentiviral vector particle numbers by real-time PCR. Biotechniques (2001) 1.09
The reprogrammed host: Chlamydia trachomatis-induced up-regulation of glycoprotein 130 cytokines, transcription factors, and antiapoptotic genes. Arthritis Rheum (2001) 1.08
Associations between coping and survival time of adult leukemia patients receiving allogeneic bone marrow transplantation: results of a prospective study. J Psychosom Res (2001) 1.07
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia (2011) 1.07
CD4+ T cell mediated intestinal immunity: chronic inflammation versus immune regulation. Gut (2005) 1.06
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol (2008) 1.06
Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture. Oncogene (2008) 1.06